Table 1 Patient demographics

From: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

Patient characteristics

Number

Total number entered

92

Age median (range)

70 (24–85)

Male/female

55/37

ECOG performance status

 

 0

30 (32.6%)

 1

50 (54.3 %)

 2

10 (10.9%)

 Unknown

2 (2.1%)

Primary site

 

 Rectum

29 (31.5%)

 Colon

63 (68.5%)

Original Dukes stage

 

 A

1

 B

12

 C

27

 D

29

 Unknown

23

Metastatic sites

 

 Liver

62

 Lung

34

 Nodal

21

 Peritoneum

8

 Locoregional

11

Histological differentiation

 

 Well

2

 Moderate

68

 Moderate–poorly

2

 Poorly

12

 Unknown

8